IL-2 (Aldesleukin)

DRUG2 trials

Sponsors

National Cancer Institute (NCI), The Methodist Hospital Research Institute

Conditions

Alzheimer Dementia (AD)Kita-kyushu Lung Cancer Antigen 1, Human

Phase 1

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

TerminatedNCT05035407

National Cancer Institute (NCI)Kita-kyushu Lung Cancer Antigen 1, Human

Start: 2022-03-08End: 2025-07-16Updated: 2025-12-02

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

RecruitingNCT07651319

The Methodist Hospital Research InstituteAlzheimer Dementia (AD)

Start: 2026-07-01End: 2029-12-01Target: 30Updated: 2026-06-16

Related Papers

A phase I trial of T-cell receptor gene therapy targeting KK-LC-1 for gastric, breast, cervical, lung and other KK-LC-1 positive epithelial cancers.

Journal of Clinical Oncology2022-06-015 citations